Close Menu

NEW YORK – Molecular diagnostics developer Curetis said on Thursday that its preliminary revenues for fiscal year 2019 rose 64 percent to €2.3 million ($2.5 million) from €1.4 million in 2018.

The company said that this revenue was realized from a total contract order volume of about €3.4 million received in 2019 compared to contract order volume of €1.1 million in 2018. Revenue growth in 2019 was primarily driven by collaborations undertaken by Curetis subsidiary Ares Genetics, as well as increased uptake of Curetis' Unyvero product line, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.